[Skip to Navigation]
October 1990

Antihelminthic Therapy for Neurocysticercosis-Reply

Author Affiliations

Research Division Instituto Nacional de Neurologia y Neurocirugia Insurgentes Sur 3877 14410 Mexico 22, DF, Mexico

Arch Neurol. 1990;47(10):1059-1060. doi:10.1001/archneur.1990.00530100019005

In Reply.  —Kramer detects some ills replicated in trials for drug treatment of neurocysticercosis conducted by us1 and by others; each of these "ills" has been previously discussed by us,2,3 actually, we believe that some points that for Kramer are ills, for us are the strength of our trials: A different protocol of drug therapy has to be planned for every disease considering its peculiarities, there is not a universal recipe for all drug trials; in our trials we have chosen imaging studies for evaluation of therapeutic response precisely to avoid the subjective clinical evaluation so highly recommended by Kramer that is quite misleading in the case of neurocysticercosis due to its complex clinical picture that depends on several factors related to number, location, stage of lesions, and individual immunological factors4; double-blind, placebo-controlled trials are useful in studies where subjective evaluation of symptoms is to be made,

Add or change institution